Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells

Acta Pharmacologica Sinica

Volumn 33, Issue 1, 2012, Pages 75-81

  Ding, Li ^a   Zhang, Jin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

atherosclerosis; diabetes mellitus; endothelial NO synthase; glucagon like peptide 1; human umbilical vein endothelial cell

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; SITAGLIPTIN;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; INCUBATION TIME; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLUCAGON-LIKE PEPTIDE 1; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDES; RECEPTORS, GLUCAGON;

EID: 84855428526     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.149     Document Type: Article

References (24)

1. Yang Z, Ming XF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 2006; 4: 53-65.
2. Bauer V, Sotnikova R. Nitric oxide-the endothelium-derived relaxing factor and its role in endothelial functions. Gen Physiol Biophys 2010; 29: 319-40.
3. Stankevicius E, Kevelaitis E, Vainorius E, Simonsen U. Role of nitric oxide and other endothelium-derived factors. Medicina (Kaunas) 2003; 39: 333-41.
4. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
5. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705. (Pubitemid 46048557)
6. Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. Curr Diab Rep 2006; 6: 194-201.
7. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-23. (Pubitemid 32755966)
8. Briones M, Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother 2006; 7: 1055-64. (Pubitemid 43949943)
9. Golpon HA, Puechner A, welte T, wichert PV, Feddersen CO. Vaso-relaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001; 102: 81-6. (Pubitemid 33135568)
10. Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nystrom T. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept 2009; 157: 8-13.
11. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008; 117: 2340-50. (Pubitemid 351653542)
12. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21: 1125-35. (Pubitemid 36667866)
13. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-15. (Pubitemid 39491964)
14. Basu A, Charkoudian N, Schrage w, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endo-crinol Metab 2007; 293: E1289-95. (Pubitemid 350106596)
15. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010; 391: 1405-8.
16. Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, Backx PH, et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010; 151: 1520-31.
17. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, witters LA, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999; 443: 285-9. (Pubitemid 29080812)
18. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-5.
19. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601.
20. Liu H, Hu Y, Simpson Rw, Dear AE. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plas-minogen [corrected] activator inhibitor-1 expression. J Endocrinol 2008; 196: 57-65. (Pubitemid 351234571)
21. Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009; 52: 199-207.
22. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114: 115-21. (Pubitemid 36773875)
23. Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab 2009; 23: 443-52.
24. Owji AA, Khoshdel Z, Sanea F, Panjehshahin MR, Shojaee Fard M, Smith DM, et al. Effects of intracerebroventricular injection of glucagon like peptide-1 and its related peptides on serotonin metabolism and on levels of amino acids in rat hypothalamus. Brain Res 2002; 929: 70-5. (Pubitemid 34164410)